2023 European Society of Hypertension (ESH) Guidelines
ESH Guidelines recommend renal denervation
for uncontrolled hypertension patients1
Renal denervation now recommended
Welcome to the turning point in hypertension care. The European Society of Hypertension (ESH), endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH), now recommends renal denervation (RDN) as a safe and effective adjunctive hypertension treatment option.1
Patient selection criteria
Patients with an eGFR >40 ml/min/1.73m2 who have uncontrolled BP despitethe use of antihypertensive drug combination therapy* or if drug treatment elicits serious side effects and poor quality of life. (Class II).
Patients with resistant hypertension if eGFR is >40 ml/min/1.73m2. (Class II).
Proven to reduce blood pressure
With over 25,000 real-world RDN patients2 *, Medtronic Symplicity™ blood pressure procedure has already proven to deliver clinically significant, safe, and sustained BP reductions in multiple clinical trials.3–8
Renal denervation
The third pillar for hypertension management.
Lifestyle modifications
Medication
Renal denervation
Get the ESH guidelines.
Access the full publication of the 2023 ESH guidelines for the management of arterial hypertension, available on the Journal of Hypertension. Renal denervation section from page 74.
See how the procedure works
Learn more about the Symplicity system, and discover its advantages
Connect with a Medtronic representative
References
1
Mancia G, Kruetz R, Brunström M et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension Endorsed by the European Renal Association (ERA) and the International Society of Hypertension (ISH). J Hypertens. Published online June 21, 2023.
2
Medtronic Data on File, RDN Catheter Historic Data, June 2023.
3
Townsend RR, et al. Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390(10108):2160-2170.
4
Böhm M, Kario K, Kandzari DE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet. May 2, 2020;395(10234):1444–1451.
5
Kandzari DE, Böhm M, Mahfoud F, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet. June 9, 2018;391(10137):2346–2355.
6
Kandzari DE et al, AHA 2022.
7
Mahfoud F, Kandzari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. Lancet. 2022;399:1401–1410.
8
Schlaich M et al, Kidney Week 2021.
Footnotes
*
Includes Symplicity Spyral™ and Flex™ catheters.
Disclaimer: See the device manual for detailed information regarding the instructions for use, indications, contraindications, warnings, precautions, and potential adverse events. For further information, contact your local Medtronic representative and/or consult the Medtronic website at cema.medtronic.com.
For distribution only in markets where the Symplicity Spyral™ multi-electrode renal denervation catheter and Symplicity G3™ renal denervation RF generator have been approved. Not for distribution in the USA, Japan, or France.